OK BIOTECH (4155) reported revenue of NT$153.3 million for Oct 2026, +19.6% year on year and -29.4% from the previous month. Revenue for Jan–Oct 2026 was NT$1.54 billion (+14.5% year on year).
Year-on-year revenue growth: 5 months in a row. →
In Oct 2026, it ranked No. 54 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$153.3 million | +19.6% | -29.4% |
| Sep 2026 | NT$217 million | +60.0% | +10.0% |
| Aug 2026 | NT$197.3 million | +49.3% | +29.1% |
| Jul 2026 | NT$152.8 million | +33.8% | -11.5% |
| Jun 2026 | NT$172.6 million | +22.9% | +24.0% |
| May 2026 | NT$139.2 million | -3.0% | +9.5% |
| Apr 2026 | NT$127.2 million | -9.4% | -13.0% |
| Mar 2026 | NT$146.2 million | -10.4% | +38.0% |
| Feb 2026 | NT$105.9 million | +10.8% | -19.4% |
| Jan 2026 | NT$131.5 million | -15.0% | +35.4% |
| Dec 2025 | NT$97.1 million | -40.6% | -13.9% |
| Nov 2025 | NT$112.8 million | -8.0% | -12.0% |
| Oct 2025 | NT$128.2 million | -11.4% | -5.5% |
| Sep 2025 | NT$135.6 million | -23.8% | +2.7% |
| Aug 2025 | NT$132.1 million | +0.1% | +15.7% |
| Jul 2025 | NT$114.2 million | -21.3% | -18.7% |
| Jun 2025 | NT$140.4 million | -17.5% | -2.1% |
| May 2025 | NT$143.5 million | +16.9% | +2.2% |
| Apr 2025 | NT$140.4 million | -3.7% | -14.0% |
| Mar 2025 | NT$163.2 million | -0.4% | +70.7% |
| Feb 2025 | NT$95.6 million | -7.7% | -38.2% |
| Jan 2025 | NT$154.7 million | +82.4% | -5.3% |
| Dec 2024 | NT$163.4 million | +71.2% | +33.2% |
| Nov 2024 | NT$122.7 million | +30.1% | -15.2% |
| Oct 2024 | NT$144.7 million | +68.0% | -18.8% |
Jan–Oct 2026 cumulative: NT$1.54 billion (+14.5% YoY)
Other Biotech & Medical companies
Compare with peers: OK BIOTECH vs PEC / OK BIOTECH vs Lotus Pharm / OK BIOTECH vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16